ALNAQ — Allena Pharmaceuticals Share News
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro Cap
Brief: Allena Pharmaceuticals Says Decided To Terminate Urirox-2 Study
NASDAQ TRADE HALT HALT NEWS PENDING AT 04:49 PM
Allena Pharmaceuticals Inc expected to post a loss of 16 cents a share - Earnings Preview
Brief: Allena Pharmaceuticals Enters Into Retention Agreements With Each Of Louis Brenner, CEO, And Richard Katz, CFO
U.S. STOCKS ON THE MOVE-Plus Therapeutics, Allena Pharam, Avrobio, Nine Energy
Allena surges on evaluation of strategic alternatives
Brief: Allena Pharmaceuticals Provides Clinical And Corporate Update
Brief: Allena Pharmaceuticals Says On Dec 23, Co Entered Into Renewed, Replacement At Market Issuance Sales Agreement With B. Riley Securities Inc
Allena Pharmaceuticals Inc reports results for the quarter ended in September - Earnings Summary
Brief: Allena Pharmaceuticals Posts Quarterly Loss Per Share Of 17 Cents
U.S. STOCKS ON THE MOVE-Activision Blizzard, Zillow, Allbirds, BioCryst
Allena Pharma jumps on fast track designation for kidney disease drug
Brief: Allena Pharmaceuticals Receives Fast Track Designation From FDA For The Development Of Hyperuricemia Drug Candidate
Allena Pharma up on starting patient dosing in gout therapy trial
Brief: Allena Pharmaceuticals Commences Dosing Of Gout Patients In Second Phase 2A Trial Of ALLN-346
U.S. RESEARCH ROUNDUP-Adobe, Goodrx Holdings, PG&E
U.S. RESEARCH ROUNDUP-Aspen Technology, Bath & Body Works, Wix.Com
Allena Pharmaceuticals Inc reports results for the quarter ended in June - Earnings Summary
Brief: Allena Pharmaceuticals Posts Quarterly Loss Per Share Of 0.24